Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

BACKGROUND: Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are increasing considered for the tailored management of resectable non-small cell lung cancer (NSCLC). This study aimed to analyze the survival and toxicity profile of patients with EGFR mutation-positive...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Transl Lung Cancer Res
Auteurs principaux: Zeng, Ziqing, Yan, Bo, Chen, Yulong, Zhang, Lianmin, Zhu, Jianquan, Yang, Fan, Wei, Feng, Tam, Terence Chi Chun, Kauffmann-Guerrero, Diego, Soo, Ross Andrew, Ren, Xiubao, You, Jian
Format: Artigo
Langue:Inglês
Publié: AME Publishing Company 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7815377/
https://ncbi.nlm.nih.gov/pubmed/33489802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-1214
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires